Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Sikkerhet og effekt av Ellacor® Micro-coring® ved etterlevelse av beste praksis for teknikk og postprosedyrale tiltak

12. november 2026 oppdatert av: Cytrellis Biosystems, Inc.

Sikkerhet og effekt av Ellacor mikro-koring etter beste praksis for teknikk og post-prosedyrale tiltak

Since its inception of being marketed in the United States in 2021, physicians have used various post procedure skin care regimen to facilitate recovery. This study aims to examine the use of three post care products in five skin care regimens

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

24

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Florida
      • Miami, Florida, Forente stater, 33173
        • Miami Dermatology And Laser Institute
    • Kentucky
      • Louisville, Kentucky, Forente stater, 42022
        • Caloaesthetics Plastic Surgery Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

45 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Male and female adult, between the ages of 45 and 65
  2. Fitzpatrick Skin Type I to IV
  3. Have moderate to severe wrinkles on the mid and lower face, according to Lemperle Wrinkle Severity Scale (LWSS), i.e. score 3, 4 or 5.
  4. Willingness to sign Informed Consent Form

Exclusion Criteria:

  1. Pregnant women or nursing mothers
  2. Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area
  3. Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine
  4. Patients with a history or presence of any clinically significant bleeding disorder

i. Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus e. Patients with systemic infections or acute local skin infections (as Hepatitis disorders type A, B, C, D, E or F or HIV infection) f. Patients who are on a high dose of anti-coagulants or blood-thinning substances, e.g., aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days g. Patients who are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area h. Patients have undergone plastic surgery of the face within the last twelve (12) months or have any facial surgical scars less than twelve (12) months old i. Patients who have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive/invasive skin treatment in the treatment area during the previous six (6) months j. Patients with scars less than six (6) months old in the treatment area k. During the study time frame, unwilling to refrain from receiving these following aesthetic treatments: toxin, filler, any skin resurfacing (laser, RF, ultrasound, microneedling, etc.); l. Have enrolled in another clinical trial during or overlapping part of this study m. Unwilling to have facial photography taken for the study purpose n. Any physical or psychological factors, in the judgment of the study investigator, may prevent subject from performing the procedure correctly.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Regenerating Skin Nectar (by Alastin) + Tegaderm

Alastin to be applied post procedure followed up Tegaderm. Tegaderm will be left on for 12 hours. Alastin will be applied twice daily for the duration of the study

ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Andre navn:
  • mikro-kjærning
  • dermal mikro-kjerneprøvetaking
  • ellacor
Aktiv komparator: Kerra+ Recovery Cream (by Quthero) + Tegaderm

Patients will receive Kerra+ post procedure followed by Tegaderm. The Tegaderm is removed after 12 hours. Kerra+ will be applied twice daily for the duration of the study.

ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Andre navn:
  • mikro-kjærning
  • dermal mikro-kjerneprøvetaking
  • ellacor
Aktiv komparator: Ariessence Platelet-Derived Growth Factor (PDGF) solution +Alastin + Tegaderm

Patients will receive PDGF immediately post procedure followed by Alastin followed by Tegaderm. The Tegaderm will be removed after 12 hours and the Alastin will continue to be applied twice daily for the duration of the study

ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Andre navn:
  • mikro-kjærning
  • dermal mikro-kjerneprøvetaking
  • ellacor
Aktiv komparator: Ariessence PDGF solution + Kerra+ Recovery Cream + Tegaderm

Patients will receive PDGF immediately post procedure followed by Kerra+ followed by Tegaderm. The Tegaderm will be removed after 12 hours and the Kerra+ will continue to be applied twice daily for the duration of the study

ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Andre navn:
  • mikro-kjærning
  • dermal mikro-kjerneprøvetaking
  • ellacor
Aktiv komparator: Tegaderm Only

Patient will only receive Tegaderm for post-care

ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.

Andre navn:
  • mikro-kjærning
  • dermal mikro-kjerneprøvetaking
  • ellacor

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Global Aesthetic Improvement Scale (GAIS)
Tidsramme: GAIS Assessment will be performed under a timeframe of 90 days

Treatment improvement will be evaluated based off the 7 grade GAIS by both the subject and the physician.

GAIS Assessment will be performed under a timeframe of 90 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Clinical Assessment
Tidsramme: Clinical assessment will be performed at each follow up throughout the study period.

Clinical assessment will be performed, and graded on a 0-3 scale on Day 0, Day 7, Day 30, and Day 90- 0 = absent, 1 = mild, 2 = moderate, 3 = severe for the following side effects:

  • Bleeding
  • Erythema - redness
  • Ecchymosis - bruising
  • Dryness, roughness
  • Crusting Tenderness
  • Numbness
  • Edema - swelling
  • Burning
  • Tightness/Pulling of Skin
  • Pain/Discomfort
  • Tingling
  • Skin Peeling
  • Circular Marks on skin
  • Any other observation
Clinical assessment will be performed at each follow up throughout the study period.

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety Outcomes
Tidsramme: Day 0 to end of study period

Safety will be evaluated throughout the duration of the study by recording adverse events on Day 0, Day 7, Day 30, and Day 90

Day 0 to end of study period
Subject Satisfaction Survey
Tidsramme: Day 90

Subject satisfaction data will be collected via a written questionnaire at the 90-day post procedure final follow-up visit. This questionnaire will be composed of 5-point Likert scale questions, as well as free-text responses. Subjects will be asked to determine overall satisfaction with the treatment. The choices will be: 1) very unsatisfied; 2) somewhat unsatisfied; 3) neither unsatisfied nor satisfied; 4) somewhat satisfied; 5) very satisfied.

Day 90

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

26. november 2025

Primær fullføring (Antatt)

1. mars 2027

Studiet fullført (Antatt)

1. april 2027

Datoer for studieregistrering

Først innsendt

19. november 2025

Først innsendt som oppfylte QC-kriteriene

2. desember 2025

Først lagt ut (Faktiske)

3. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2025

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere